H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release

Wave Life Sciences Ltd. (NASDAQ:WVE) ranks among the best CRISPR stocks to buy. On June 23, H.C. Wainwright maintained its $22 price target and Buy rating on Wave Life Sciences Ltd. (NASDAQ:WVE). The rating, in line with the strong analyst consensus on the company, follows new preclinical evidence that was presented at the 85th ADA meeting in Chicago.

H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release

The firm cited data from WAVE’s WVE-007 program that showed that in diet-induced obese mice, lowering INHBE mRNA with a single subcutaneous injection of INHBE-03 led to considerable weight loss.

More specifically, the preclinical findings showed that the only way treated mice lost weight was by losing fat mass in their epididymal white adipose tissue; in contrast, the quadricep muscle mass, which is a crucial therapeutic differentiator, was constant.

Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company that employs PRISM, a platform for drug research and discovery, to create and market RNA (ribonucleic acid) therapies.

While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.